Concomitant use of angiotensin system inhibitors may significantly improve overall survival and progression-free survival in patients with metastatic renal cell carcinoma (mRCC) receiving sunitinib, a study published in the journal Annals of Oncology has shown.
For the study, researchers retrospectively analyzed data from all patients with mRCC who received sunitinib as first-line treatment at a single cancer institute in France between 2004 and 2013.
Researchers identified 213 patients with a median follow-up of 3.6 years. Of those, 134 were hypertensive and 105 used angiotension system inhibitors.
Results showed that hypertensive patients had a longer median overall survival (41.6 vs 16.4 months; P < 0.0001) and a longer median progression-free survival (12.9 vs 5.6 months; P < 0.0001) compared with non-hypertensive patients.
RELATED: Adding More Dietary Lycopene May Help Protect Against Kidney Cancer
In addition, multivariate analysis showed that those who took angiotensin system inhibitors had significantly better overall survival (HR = 0.40; 95% CI: 0.24-0.66; P < 0.001) and progression-free survival (HR = 0.55; 95% CI: 0.35-0.86;P = 0.009) compared with non-users.
Researchers found no difference on outcome between patients who started taking angiotensin system inhibitors before initiating sunitinib and those started during sunitinib treatment.